cyrilzakka/clinical-trials huggingface dataset:
Computerized Intervention of Parental Involvement in Diabetes Care of Their Child

The purpose of this study is to develop an intervention to increase parental motivation for supervision and monitoring youth diabetes care behavior. The intervention will be tested in three brief session in conjunction with regularly scheduled diabetes clinic visits and delivered through a computer program based in the principles of Motivational Interviewing.

The study includes a development phase (Phase 1: development of the intervention followed by feasibility testing with 10 youth and 10 parents) and a pilot validation phase \[Phase 2: pilot randomized clinical trial (RCT)\] using a sample of 90 African American youth transitioning to independent diabetes care and their parents. In this phase, families will be randomly assigned to one of three study arms: parent motivation for monitoring and youth motivation for diabetes care (arm 1), parent motivation for monitoring and youth information (arm 2) or parent and youth information (arm 3). In phase 1 (development), youth and their caregivers will complete a one-time research visit where they use the program and provide feedback via a semi-structured interview regarding the usefulness of the content, its user-friendliness and make suggestions for changes to enhance acceptability. In phase 2 ( RCT), families will complete three intervention plus data collection visits and one additional data collection only visit. Research visits will be scheduled to coincide with appointments in the diabetes clinic to maximize convenience for families.

Eligibility Criteria:
Inclusion Criteria:

* African American race/ethnicity
* Age: 10 years 0 months - 12 years, 11 months
* Type 1 diabetes mellitus
* Diagnosed at least 6 months
* Patient of Children's Hospital of Michigan Diabetes Clinics
* English fluency, both verbal and written

Exclusion Criteria:

* Psychiatry/psychological diagnoses including cognitive impairment that would prevent the participant from understanding the data collection measures, (i.e. moderate or severe mental retardation) or the following psychiatric diagnoses: autism and schizophrenia. Youth with current suicidal intent are not enrolled until psychiatrically stable.
* Medical diagnoses that would result in atypical diabetes management i.e. cystic fibrosis. Other medical conditions that would not affect diabetes management, such as asthma, do not exclude the participant from study participation.
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation

The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (INR) adjusted-dose warfarin in patients with atrial fibrillation (AF).

The end of the study is defined by a common study end date for all participants, defined as 9 months (39 weeks) after the last participant randomized.

All participants will receive oral warfarin (or matching placebo) and weekly SC injections of idrabiotaparinux sodium (or matching placebo) up to 6 months before the common study end date. All participants are expected to be treated for at least 6 months.

All participants will have then an 6-month observational period after cessation of study treatment.

Eligibility Criteria:
Inclusion Criteria:

* Non valvular atrial fibrillation (AF)
* Indication for long-term Vitamin-K antagonist (VKA) therapy based on the presence of previous ischemic stroke, transient ischemic attack (TIA) or systemic embolism and/or at least two of the following risk factors: hypertension requiring drug treatment, moderately or severely impaired left ventricular function and/or congestive heart failure, age \> or = 75 years, diabetes mellitus.

Main exclusion Criteria:

* Indication for VKA other than AF
* Stroke or TIA within previous 5 days
* Transient AF caused by a reversible disorder
* Planned major surgery/trauma or cardioversion within 30 days
* INR \> 3 at baseline
* Active bleeding or high risk of bleeding
* Uncontrolled hypertension
* Pregnancy or childbearing potential without proper contraceptive measures or breast feeding.
Iron Status in Children With ADHD

Evaluation of the status of iron deficiency in children with attention deficit hyperactivity disorder.

Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent neurodevelopmental disorders, affecting \~5-8% of children worldwide. For about 60% children with ADHD, the symptoms persist into adulthood. Individuals with ADHD have poorer educational and social outcomes, increased injury incidences during daily activities and an elevated risk of developing more severe mental disorders.

Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder defined by persistent, impairing and developmentally inappropriate inattentive/disorganized and/or hyperactive/impulsive behaviors that lie at the far end of a normally distributed continuum.

Dopamine is one of the key neurotransmitters in the brain. Besides its regulatory role in motor and limbic functions, dopamine also regulates cognition, attention, and reward, each of which is impaired in ADHD. The nigrostriatal dopamine pathway is involved in motor control, while the mesolimbic dopamine pathway is involved in motivation and reinforcement learning. The mesocortical dopamine pathway originating in the ventral tegmental area (VTA) and projecting to the prefrontal cortex (PFC) plays a role in cognitive functioning.

Brain iron homeostasis may be important in the pathophysiology of ADHD because iron is a cofactor of the rate-limiting enzyme tyrosine hydroxylase, which is required for dopamine synthesis in the metabolism of dopamine and the hypodopaminergic state of the brain in ADHD results in the symptoms of the disorder. Moreover, iron is colocalized with dopamine in the brain of children with ADHD.

In children, iron deficiency can therefore lead to delayed cognitive, motor, attention and memory deficits, visual and auditory deficits, decreased school performance, and/or behavioral disorders, some with persistent long-term effects.

WHO defines anemia in a population as a mild, moderate, or severe public health problem if its prevalence is 5-20%, 20-40%, or \>40%, respectively. Most of the WHO countries have a moderate-to-severe public health problem with anemia, i.e., over 20% of women and young children are affected. In developing countries, diets with poor iron bioavailability are the primary cause of iron deficiency anemia.

There is a high demand for dietary iron during infancy and preschool years to support physical growth, rapid brain development, and early learning capacity.Prompt identification and treatment of anemia leads to overall improvement of population health outcomes, improved physical exercise performance, and well-being that results in enhanced economic productivity.

Eligibility Criteria:
Inclusion Criteria:

* All children above 4 years and under 12 years old diagnosed with attention deficit hyperactivity disorder (ADHD) according to DSM-V criteria.
* Not receiving iron therapy

Exclusion Criteria:

* Children under 4 years old
* Above 12 years old
* Not diagnosed attention deficit hyperactivity disorder(ADHD)
* Any other associated neurological disorder
Evaluation Of An Advanced Borderless Dressing

This study will gather preliminary clinical, health economic, and safety data on the treatment of chronic wounds with the ALLEVYN Life Non-Bordered dressing compared to standard of care treatment when used on a wound.

The study is a pilot RCT, which will generate the first comparative clinical, economic, and safety data for use of ALNB in subjects. A small sample of subjects with a range of chronic, moderate to highly exuding ulcer types (LU \[arterial/mixed etiology leg ulcers or venous leg ulcers requiring compression therapy\], PU, and non-ischemic DFU) will be enrolled and followed for 12 weeks to study the impact on health-related quality of life, ulcer progression and healthcare resource utilization.

Eligibility Criteria:
INCLUSION CRITERIA

1. The subject must provide informed consent to participate in the study.
2. The subject must be eighteen (18) years of age or older.
3. The subject must be willing and able to make all required study visits.
4. The subject must be able to follow instructions and be deemed capable of completing the CWIS questionnaire.
5. The subject must present with a chronic (≥ 4 weeks duration) ulcer which meets all of the following criteria:

   1. The ulcer is classified as either:

      * a pressure ulcer
      * a non-ischemic diabetic foot ulcer
      * a leg ulcer (arterial/mixed etiology leg ulcers or venous leg ulcers requiring compression therapy)
   2. The ulcer is, in the opinion of the Investigator, moderate to highly exuding.
   3. The ulcer would, in the opinion of the Investigator, benefit from a protective dressing.
   4. The ulcer is not infected based on clinical signs/symptoms.
6. A subject with a DFU must have an ankle-brachial index (ABI) of 0.7 or greater, as measured within 30 days of the Screening Visit.

EXCLUSION CRITERIA

1. Contraindications or hypersensitivity to the use of the ALLEVYN LIFE Non-Bordered, comparator, ancillary products, or their components.
2. Participation in the treatment period of another clinical trial within 30 days of Visit 1 or planned participation overlapping with this study.
3. The subject's reference ulcer is being treated with a topical antimicrobial dressing.
4. Subjects with skin features (e.g. tattoos, skin color, pre-existing scarring) which, in the opinion of the Investigator, could interfere with the study assessments.
5. Subjects who have participated previously in this clinical trial.
6. Subjects with a history of poor compliance with medical treatment.
7. Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer

Treatment of patients with locally advanced esophageal cancer (EC) is multidisciplinary and consists of neoadjuvant therapy followed by surgical removal of the esophageal tumor and potentially tumor positive lymph nodes. The beneficial effect of the addition of immunotherapy to improve response rates to current treatment strategies has been investigated response to, since only 16 to 43% of EC patients achieve a pathological complete response (pCR) after neoadjuvant therapy and a pCR is associated with better long-term outcomes. Unfortunately, not all patients respond to immunotherapy and the knowledge about biomarkers that predict response to therapy are required. A promising novel parameter is tumor programmed death-ligand 1 (PD-L1) expression, one of the immune checkpoints targeted by cancer immunotherapy. Studies performed in patients with various solid tumors demonstrate improved response to immunotherapy and survival benefit in patients with higher PD-L1 expression. Nonetheless, not all patients with high PD-L1 expression show benefit and some without expression do. Moreover, mostly biopsy-based tests are used to assess PD-L1 status, although these tests are prone to errors, partly due to heterogeneity in tissue expression. Novel methods are needed to gain more insight in the PD-L1 expression in order to better select patients who are likely to benefit from immunotherapy. The investigators hypothesize that quantitative fluorescence endoscopy using the tracer durvalumab-680LT targeting PD-L1 is a promising technique to investigate the heterogeneity of PD-L1 expression.


Eligibility Criteria:
Inclusion Criteria:

* Lesion suspected for locally advanced EC (cT1b-4a N0-3 M0)
* Indication for neoadjuvant therapy
* Age ≥ 18 years;
* Written informed consent.

Exclusion Criteria:

* Medical or psychiatric conditions that compromise the patient's ability to give informed consent according to treating medical physician;
* Concurrent uncontrolled medical conditions according to treating medical physician;
* Medical history of auto-immune disease
* Pregnancy or breast feeding. A negative pregnancy test must be available for women of childbearing potential (i.e. premenopausal women with intact reproductive organs and women less than two years after menopause);
* Irradical endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) of the primary tumor prior to start of neoadjuvant therapy according to the patient's medical history;
* Received an investigational drug within 30 days prior to the dose of durvalumab-680LT according to the patient's medical history;
* History of infusion reactions to durvalumab or other monoclonal antibodies according to the patient's medical history;
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device

The aim of the study is to evaluate an objective, non-invasive optical device able to quantify, without eye contact, the width of the irido-corneal angle and to better identify cases of narrow angle or angle closure that may be prevented with relatively simple treatments.

Worldwide, glaucoma has been identified as a leading cause of blindness, second only to cataract. The two most common types of glaucoma are primary open-angle and angle closure glaucoma (PACG), both characterized by progressive and irreversible degeneration of the retinal ganglion cells and axons. In PACG, the optic neuropathy occurs as a consequence of raised intraocular pressure (IOP) resulting from physical obstruction of aqueous outflow or degenerative changes in the trabecular meshwork. Angle closure is the result of an anatomic characteristic that causes closure of the drainage angle by synechial or appositional approximation between the iris and the trabecular meshwork, blocking access to aqueous humor. Although the most common mechanism responsible for angle closure is relative pupillary block, this is not the only one. Angle crowding can be caused by plateaus iris, or by multiple mechanisms such as choroidal thickness and uveal expansion.

A careful analysis of the anterior chamber angle is considered the main management strategy for PACG. The Van Herick grading of limbal anterior chamber depth is considered a screening tool for the estimation of angle width although gonioscopy remains the clinical reference standard for assessing the presence of narrow or closed angle. Ultrasound biomicroscopy, Scheimpflug imaging and anterior segment optical coherence tomography are considered as non-invasive alternatives to gonioscopy. However, these techniques are expensive and also have drawbacks. Therefore, there is a need for an easy and objective method able to evaluate the angle width for screening purposes in clinical practice.

Based on these findings, the purpose of the present study is to evaluate an objective, non-invasive optical device able to quantify, without eye contact, the width of the irido-corneal angle and to better identify cases of narrow angle or angle closure that may be prevented with relatively simple treatments.

Eligibility Criteria:
Inclusion Criteria:

* Willingness to participate and ability to understand and sign an informed consent.
* 18 years of age or older.
* Healthy subjects, patients with PACS or angle closure as defined by the EGS Guidelines.
* The right eye will be included in the study for all patients, unless a clinical contraindication to the examination is present.

Exclusion Criteria:

* Inability to understand and sign an informed consent.
* Any prior ocular surgery or laser treatment with the potential to alter the natural anatomy of the anterior segment of the eye.
* Corneal or conjunctival abnormalities that preclude an adequate view of the anterior chamber.
Chlorhexidine Drying Time

Before a patient gets a spinal/epidural, their lower back is cleaned with an antiseptic solution diluted in alcohol called ChloraPrep. ChloraPrep must completely dry before starting the anesthetic procedure. It is not known how much time is needed for the solution to completely dry. The investigators aim to determine this.

As the ChloraPrep dries, the alcohol is converted into vapour. The investigators will be using a PPBRae 3000 device to detect small amounts of vapours in the air. As the ChloraPrep dries it gives off less and less vapour. The investigators will use this diminishing vapour concentration to determine when drying is complete.


Eligibility Criteria:
Inclusion Criteria:

* Pregnant
* At full term
* Due to have a cesarean section under spinal or epidural anesthesia
* 19 to 40 years of age

Exclusion Criteria:

* Allergy to certain antiseptic solutions
* Not suitable for a spinal/epidural anesthetic
* Have a significant amount of hair on lower back
The Charlson Comorbidity Index: Predicting Severity in Emergency Departments

Objective: The Charlson Comorbidity Index (CCI) is a comorbidity scale used widely throughout the world. It uses patients' preoperative and intraoperative morbidity factors to evaluate morbidity and mortality risk. Though the CCI has widespread use, it has not been evaluated in patients attending at ES, and its relationship with patient readmission has not been shown previously. In this study, we aimed to show whether there is a correlation between the CCI value and the number of repeated admissions to emergency services and that the CCI value can be used as a predicted factor for the serious patients.

Matherials and Methods: This was a prospective observational cross-sectional study. Age, gender, vital signs of the patients who agreed to participate in the study was recorded. Numbers of emergency service applications in the last 6 months and CCI score have been recorded.

This study showed that CCI score can be used for identify serious patient in emergency service.

Eligibility Criteria:
Inclusion Criteria:

* Admitted patients were told about the study, and those who agreed to participate were included

Exclusion Criteria:

* Patients who did not wish to participate in the study
* Patients who were unable to work or who had problems with consciousness
* Patients with non-hospital cardiopulmonary arrest
* Patients who had previously participated in the study (readmitted patients)
* Patients who had accessed ES for the same or a similar complaint within the last seven days
* \< 18 years' old
Pharmacodynamic Trial, of Slow Release ASA, in Platelet Functionalism, a Long Term Treatment Period

Evaluation of the pharmacodynamic profile (antiaggregant profile, balance of prostanoids and nitric oxid) of a ASA-SR (slow-release)formulation in comparison with a ASA NR (normal release), 150 mg, during 12 months of treatment.

* A large clinical trials have established the efficacy of the antiaggregant products in patients with ischemic cardiopathy, stroke and intermittent claudication.
* The acetylsalicylic acid (ASA) is the most used antiaggregant substance, nevertheless, and spite of being centenarian, it last some questions pending regarding the most appropriate dose, mechanisms of action implicated, the association with oder drugs, and the pharmaceutical fom in order to improve the efficacy and safety of the ASA.
* Some previous studies indicate that the slow release form of ASA has a different behaviour in the platelet effect in comparison with plain formulation.
* The aim of this study is to demonstrate the best antiaggregant and safety profile of a low dose of a slow release formulation in a long term treatment period of one year.

Eligibility Criteria:
Inclusion Criteria:

* Previous episodes of myocardial infarction
* Previous episodes of instable angina pectoris
* Previous coronary revascularization
* Significant arterial coronary disease

Exclusion Criteria:

* Patients with other pathologies that require treatment with other antiaggregants
* Patients in treatment with low molecular weight heparin or oral anticoagulants
* Patients with antecedents of hypersensibility to ASA
ScanNav Anatomy PNB FDA Data Collection Plan

To gather additional training and/or validation data (recorded ultrasound scans) for ScanNav Anatomy PNB in the following categories:

* Femoral Nerve (Femoral)
* Interpectoral (PECS I) and pectoserratus (PECS II)
* Transversus abdominis plane (TAP)
* Serratus Plane (SP)
* Infra-inguinal Facia Iliaca (Infra-inguinal FI) Data will be collected in the form of "scenes" (target block view) and "non-scenes" (areas adjacent to the target block view).


Eligibility Criteria:
Inclusion Criteria:

* Male or female, at least 18 years of age;
* Able to comprehend and sign the Informed Consent prior to enrolment in the study.

Exclusion Criteria:

* Aged \<18 years of age;
* Unwilling or unable to provide informed consent.
* Previous history of medical interventions that may affect the anatomy of the chosen scan areas, e.g. hip replacements.
Bullying Experiences Among Alexandria Faculty of Medicine Students

A cross-sectional study was conducted at Faculty of Medicine, Alexandria to study the prevalence, types and consequences of bullying among medical students. An online survey was distributed among medical students. The data collection continued for two academic years: 2021-2022 and 2022-2023.

A survey based Study was implemented. Questionnaire was used to collect sociodemographic data, exposure to different types if bullying, response and consequences of bullying

Eligibility Criteria:
Inclusion Criteria:

* medical students enrolled at undergraduate or graduate programs of Faculty of medicine who were exposed to bullying

Exclusion Criteria:

* medical students who were not exposed to hullying
The Effect of Repetitive Transcranial Magnetic Stimulation for Poststroke Dysphagia Recovery

Dysphagia is one of severe complications among stroke survivors. Dysphagia is usually associated with high levels of morbidity, mortality, and financial cost. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown promise to facilitate poststroke dysphagia. However, most researches were preliminary studies in the past. The present study aims to investigate the immediate and long-term efficacy of high frequency rTMS on chronic dysphagic patients.

rTMS protocol: 5 Hz real or sham stimulation, 10 minutes per day, for 10 week-days.

Eligibility Criteria:
Inclusion Criteria:

* Poststroke dysphagia more than 3 months

Exclusion Criteria:

* Hx of seizure or a metalic device in brain or chest
AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

This multicenter, single-arm observational study will evaluate the clinical benefits of Avastin (bevacizumab) in combination with paclitaxel in first-line treatment in patients with metastatic breast cancer. Patients with metastatic breast cancer who have started Avastin treatment within 6 months prior to study start will also be eligible. Data will be collected from patients for up to 5 years.


Eligibility Criteria:
Inclusion Criteria:

* Patients with metastatic breast cancer initiated on first-line treatment with Avastin in combination with paclitaxel according to the current Hungarian summary of Product Characteristics
* Patients with metastatic breast cancer initiated within 6 months before the start of the study on treatment with Avastin according to the current Hungarian Summary of Product Characteristics

Exclusion Criteria:

Contraindications for Avastin according to the current Hungarian Summary of Product Characteristics:

* Hypersensitivity to active ingredient of Avastin or to any excipients
* Hypersensitivity to products produced in Chinese hamster cells or to other recombinant or humanized antibodies
* Pregnancy
* Untreated central nervous system metastases